View Older Stories View More Recent Stories

Feb 27, 2017 06:59AM Exelixis and Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcinoma
Feb 17, 2017 05:02PM Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Feb 7, 2017 04:05PM Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15
Feb 2, 2017 04:05PM Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017
Jan 31, 2017 04:05PM Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 30, 2017 06:00PM Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
Jan 9, 2017 05:13AM Update on Dispute between Exelixis and Genentech, a Member of the Roche Group
Jan 3, 2017 06:07PM Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 21, 2016 01:00AM Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
Dec 21, 2016 01:00AM Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada
Dec 7, 2016 08:00AM Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
Nov 30, 2016 04:15PM Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14
Nov 21, 2016 04:17PM Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29
Nov 7, 2016 04:05PM Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15
Nov 7, 2016 08:54AM Exelixis (EXEL) Presents New Data on Cobimetinib Combo Trials in Adv. Melanoma
Nov 7, 2016 01:00AM Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentech’s Planned Phase 3 Pivotal Trials
Nov 3, 2016 04:07PM Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
Oct 20, 2016 04:21PM Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016
Oct 10, 2016 06:16AM Exelixis (EXEL) Announces Statistically Significant Data from Cabozantinib Phase 2 in RCC
Oct 10, 2016 02:15AM Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016
Oct 7, 2016 07:38AM Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600
Oct 7, 2016 07:36AM Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors
Oct 7, 2016 04:01AM Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress
Oct 7, 2016 04:00AM Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors
Oct 3, 2016 04:05PM Exelixis and Ipsen to Host Investor and Media Briefing to Discuss Data Presented at the ESMO 2016 Congress
Sep 26, 2016 06:06AM Exelixis (EXEL) Announces Initiation of CS-3150 Phase 3 as Selective Mineralocorticoid Receptor Antagonist
Sep 26, 2016 06:02AM Exelixis Elects Julie Anne Smith to Its Board of Directors
Sep 26, 2016 06:00AM Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist
Sep 21, 2016 06:31AM Exelixis (EXEL) Updates Timing of Key Cabozantinib Clinical Data Presentation
Sep 20, 2016 04:55PM Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress
Sep 14, 2016 06:16AM Exelixis (EXEL) Receives EC Approval of CABOMETYX as RCC Treatment Following VEGF-Targeted Therapy
Sep 14, 2016 01:00AM European Commission Approves CABOMETYX™ (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma Following VEGF-Targeted Therapy
Sep 6, 2016 05:10PM Exelixis (EXEL) Updates on Cabozantinib Phase 3 in Adv. HCC; IDMC Says Study Should Continue Unmodified
Sep 6, 2016 05:08PM Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma
Aug 31, 2016 04:17PM Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
Aug 31, 2016 08:35AM Exelixis (EXEL) Says Data from Trials of Cabozantinib and Cobimetinib Will be Subject of 15 Presentations at ESMO
Aug 31, 2016 08:30AM Exelixis-discovered Compounds To Be Featured in 15 Presentations at the ESMO 2016 Congress
Aug 24, 2016 08:30AM Exelixis Announces Redemption of All Remaining 4.25% Convertible Senior Subordinated Notes Due 2019
Aug 3, 2016 04:06PM Exelixis Announces Second Quarter and Year to Date 2016 Financial Results and Provides Corporate Update
Jul 22, 2016 10:30AM Exelixis (EXEL) and Ipsen Announces Positive CHMP Opinion for Cabometyx to Treat Advanced RCC
Jul 22, 2016 10:25AM Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy
Jul 12, 2016 04:19PM Exelixis to Release Second Quarter 2016 Financial Results on Wednesday, August 3, 2016
Jun 6, 2016 07:35AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 6, 2016 07:30AM Exelixis (EXEL), Ipsen Announce Positive METEOR Trial Subgroup Analyses in RCC
Jun 6, 2016 07:30AM Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX™ (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO A
Jun 5, 2016 07:53AM Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Re
Jun 5, 2016 07:35AM Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced re
Jun 5, 2016 07:30AM Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting
May 23, 2016 09:05AM Exelixis (EXEL) Announces Cabozantinib Phase 2 Met Primary Endpoint in RCC
May 23, 2016 09:02AM Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell
View More Recent Stories View Older Stories